# A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)

> **NCT07293897** · — · RECRUITING · sponsor: **Takeda** · enrollment: 50 (estimated)

## Conditions studied

- Alagille Syndrome (ALGS)
- Progressive Familial Intrahepatic Cholestasis (PFIC)

## Interventions

- **DRUG:** Maralixibat

## Key facts

- **NCT ID:** NCT07293897
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-13
- **Primary completion:** 2031-06-30
- **Final completion:** 2031-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07293897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07293897, "A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07293897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*